Morgan Stanley’s Clinuvel Pharmaceuticals CUVL Stock Holding History

Morgan Stanley’s Portfolio CUVL Stock Details CUVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$35.8K	Buy	+6,000	New	+$39K	﹤0.01%	6685

Other funds holding CUVL

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Shade Tree Advisors Saratoga Springs, New York $187M AUM 53.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Morgan Stanley's CUVL Position: Q3 2026 in Review

Morgan Stanley opened a new position in Clinuvel Pharmaceuticals (CUVL) in Q3 2026: 6,000 shares worth $35.8K. The stake represents ﹤0.01% of the portfolio and ranks #6685 among its holdings.

6 funds tracked by Wall St. Rank hold CUVL as of Q3 2026.

Morgan Stanley held 6,000 shares of Clinuvel Pharmaceuticals worth $35.8K as of Q3 2026.
Clinuvel Pharmaceuticals was a new Morgan Stanley position in Q3 2026.
Clinuvel Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #6685 holding.
6 funds tracked by Wall St. Rank held Clinuvel Pharmaceuticals as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.